Methylene Blue for the Prevention of Hypotension During Hemodialysis

Summary

Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.

Timeline

Start

2021-10-21

Primary completion

2025-12-16

Completion

2025-12-16

Drugs

Indications